Cannasouth has received a manufacturing licence authorising the production of GMP-certified dried cannabis flower medicine at its cultivation facility in the Waikato region.
CEO Mark Lucas said: "Achieving the globally recognised GMP standard for our commercial-scale facility opens doors to high-value markets worldwide, while also enabling us to launch products in New Zealand.
"We are seeing exponential growth in demand for GMP flower in Australia and Europe, with no signs of [that] slowing down, and a similar trend in New Zealand is quickly developing. This validates our strategy to invest in this area."
Lucas also noted that the licence allows the company to bring medicinal cannabis production in-house "without relying on third-party manufacturing steps".
Cannasouth's proposed merger with Bay of Plenty-based Eqalis was recently approved by shareholders.
